The hearings come as part of an 18-month investigation first led by the late Rep. Elijah Cummings, D-Md., in 2019.
Below are the six drugs the committee included in its probe, according to STAT:
- Revlimid, a multiple myeloma drug manufactured by Bristol Myers Squibb
- Copaxone, a multiple sclerosis drug manufactured by Teva
- Enbrel, an autoimmune disease drug manufactured by Amgen
- Sensipar, a secondary hyperparathyroidism drug manufactured by Amgen
- H.P. Acthar, hormone gel manufactured by Mallinckrodt
- Gleevec, a chemotherapy drug manufactured by Novartis
More articles on pharmacy:
10 recent exec moves affecting the pharma industry
Pfizer to give $22M in drugs to Strategic National Stockpile
7 former FDA commissioners write opinion column lamenting White House’s treatment of agency
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.